Gavin Hirst

Gavin Hirst joined Atomwise as the Chief Scientific Officer in September 2022, where he oversees all drug discovery initiatives. He brings a wealth of experience, having worked in drug discovery for over 30 years across both large pharmaceutical companies and biotechnology firms. Prior to joining Atomwise, Hirst served as the interim Chief Scientific Officer at Turning Point Therapeutics, which was acquired by Bristol Myers Squibb in June 2022 for $4.1 billion. His career includes significant leadership roles at major pharmaceutical companies such as Janssen, Takeda, and Abbvie, where he advanced multiple small molecule assets into clinical stages and beyond. Hirst’s expertise spans several therapeutic areas, notably immunology and oncology. He earned his Ph.D. in organic chemistry from the University of Southampton and completed his post-doctoral studies at the University of California, Irvine.